1. Home
  2. BAFN vs ENTX Comparison

BAFN vs ENTX Comparison

Compare BAFN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • ENTX
  • Stock Information
  • Founded
  • BAFN 1999
  • ENTX 2010
  • Country
  • BAFN United States
  • ENTX Israel
  • Employees
  • BAFN N/A
  • ENTX N/A
  • Industry
  • BAFN Savings Institutions
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BAFN Finance
  • ENTX Health Care
  • Exchange
  • BAFN Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • BAFN 70.2M
  • ENTX 69.6M
  • IPO Year
  • BAFN N/A
  • ENTX 2018
  • Fundamental
  • Price
  • BAFN $16.36
  • ENTX $1.64
  • Analyst Decision
  • BAFN
  • ENTX Strong Buy
  • Analyst Count
  • BAFN 0
  • ENTX 1
  • Target Price
  • BAFN N/A
  • ENTX $10.00
  • AVG Volume (30 Days)
  • BAFN 10.9K
  • ENTX 47.3K
  • Earning Date
  • BAFN 04-24-2025
  • ENTX 03-28-2025
  • Dividend Yield
  • BAFN 1.96%
  • ENTX N/A
  • EPS Growth
  • BAFN 134.19
  • ENTX N/A
  • EPS
  • BAFN 2.62
  • ENTX N/A
  • Revenue
  • BAFN $83,769,000.00
  • ENTX $181,000.00
  • Revenue This Year
  • BAFN N/A
  • ENTX N/A
  • Revenue Next Year
  • BAFN N/A
  • ENTX N/A
  • P/E Ratio
  • BAFN $6.30
  • ENTX N/A
  • Revenue Growth
  • BAFN 10.60
  • ENTX N/A
  • 52 Week Low
  • BAFN $10.40
  • ENTX $1.41
  • 52 Week High
  • BAFN $19.75
  • ENTX $3.35
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 35.97
  • ENTX 33.28
  • Support Level
  • BAFN $16.00
  • ENTX $1.62
  • Resistance Level
  • BAFN $19.00
  • ENTX $1.75
  • Average True Range (ATR)
  • BAFN 1.07
  • ENTX 0.10
  • MACD
  • BAFN -0.36
  • ENTX -0.02
  • Stochastic Oscillator
  • BAFN 18.31
  • ENTX 4.35

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: